The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.

Sanchez, Cecilia G; Molinski, Steven V; Gongora, Rafael; Sosulski, Meredith; Fuselier, Taylor; MacKinnon, Stephen S; Mondal, Debasis; Lasky, Joseph A

Sanchez, Cecilia G; Molinski, Steven V; Gongora, Rafael; Sosulski, Meredith; Fuselier, Taylor; MacKinnon, Stephen S; Mondal, Debasis; Lasky, Joseph A.

Affiliation

Sanchez CG; Tulane University Health Sciences Center, New Orleans, Louisiana.
Molinski SV; Cyclica, Toronto, Ontario, Canada.
Gongora R; Tulane University Health Sciences Center, New Orleans, Louisiana.
Sosulski M; Tulane University Health Sciences Center, New Orleans, Louisiana.
Fuselier T; Tulane University Health Sciences Center, New Orleans, Louisiana.
MacKinnon SS; Cyclica, Toronto, Ontario, Canada.
Mondal D; Tulane University School of Medicine, New Orleans, Louisiana.
Lasky JA; Tulane University Health Sciences Center, New Orleans, Louisiana.

Arthritis Rheumatol ; 70(1): 115-126, 2018 01.

Article in En | MEDLINE | ID: mdl-28940894

Subject(s)

Anti-Retroviral Agents/pharmacology; Cell Differentiation/drug effects; Nelfinavir/pharmacology; Pulmonary Fibrosis/drug therapy; Scleroderma, Systemic/drug therapy; Animals; Cell Culture Techniques; Computer Simulation; Disease Models, Animal; Fibroblasts/drug effects; Fibroblasts/pathology; Humans; Lung/pathology; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis/complications; Scleroderma, Systemic/complications; Signal Transduction/drug effects; Skin/pathology; Transforming Growth Factor beta1/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Fibrosis / Scleroderma, Systemic / Cell Differentiation / Nelfinavir / Anti-Retroviral Agents Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Arthritis Rheumatol Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google